Optics News

The Vision Council has released findings from its Focused inSights 2022: Digital Habits survey, which highlight recent developments in telehealth and increased technology use in optometry, according to a council press release.

Johnson & Johnson Vision announced that the FDA approved a parameter expansion for Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Management from 4 D to 6 D.

SAN DIEGO — Alcon announced plans to introduce a toric design for its Total30 contact lenses in early 2023, according to company executives who spoke during a press conference for the company’s 75th anniversary at Academy 2022.

SAN DIEGO — The CureSight home treatment technology for amblyopia produced results better than patching in a randomized controlled study, NovaSight CEO Ran Yam said at a virtual press conference held during Academy 2022.

Health Canada has approved Johnson & Johnson Vision’s Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Management, the company announced in a press release.

SAN DIEGO — Diffusion Optics Technology spectacle lenses were safe and statistically significantly reduced axial length at 3 years in children who began treatment between ages 6 and 10 years, according to a study presented at Academy 2022.

SAN DIEGO — Data from a 7-year clinical study of the MiSight 1-Day myopia control lens indicated that the fastest progressing eyes slowed the most during treatment, as reported at a virtual press conference held during Academy 2022.

SAN DIEGO — Preliminary data from a 3-year, phase 3 clinical trial of Vyluma’s NVK002 supported its safety and efficacy as a potential treatment for myopia progression in children, according to a press release from the company.

Outside of eye care, the term “presbyopia” is not commonly used or well understood — and it’s one that can be tricky to explain.

NovaSight announced in a press release that CureSight, a digital therapy device for amblyopia, has gained 510(k) clearance from the FDA.